Metoprololtartraat Cf (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, diminishing the effects of adrenaline and noradrenaline. This reduces heart rate, contractility, and conduction velocity, leading to lower cardiac output, decreased blood pressure, and reduced myocardial oxygen demand.

The appropriate dose of Metoprololtartraat Cf is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may be adjusted over time and should follow the prescriber’s specific instructions.

Safety data for metoprolol tartrate in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metoprolol tartrate is a cardio‑selective (β1‑selective) beta blocker, offering a lower risk of bronchospasm compared with non‑selective agents like propranolol. Its once‑ or twice‑daily dosing and well‑studied cardiovascular benefits make it a common choice for hypertension, angina, and heart‑failure management.

Metoprololtartraat Cf should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metoprololtartraat Cf is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and masking of hypoglycaemia symptoms in diabetic patients. Patients should be monitored for these events, especially during dose initiation or adjustment.

Metoprololtartraat Cf is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.